The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children

被引：0
|
作者：
Annemarie Rosan Kreeftmeijer-Vegter
Anthonius de Boer
Roselinda H van der Vlugt-Meijer
Peter J de Vries
机构：
[1] Utrecht University,Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology
[2] ACE Pharmaceuticals BV,Department of Internal Medicine
[3] Tergooi Hospital,undefined
来源：
Orphanet Journal of Rare Diseases | / 9卷
关键词：
European paediatric drug regulation; Orphan drug development; Paediatric use; Paediatric investigation plan; Rare diseases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children
    Kreeftmeijer-Vegter, Annemarie Rosan
    de Boer, Anthonius
    van der Vlugt-Meijer, Roselinda H.
    de Vries, Peter J.
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [2] THERAPEUTIC BENEFIT OF ORPHAN DRUGS IN ONCOLOGY: EVIDENCE AT THE POINT OF EUROPEAN MARKETING AUTHORISATION
    Odnoletkova, I
    Marjenberg, Z.
    Pooley, N.
    Langham, S.
    [J]. VALUE IN HEALTH, 2019, 22 : S491 - S491
  • [3] PREDICTING ORPHAN DESIGNATION AND MARKETING AUTHORISATION BASED ON A REVIEW OF THE EUROPEAN MEDICINES AGENCY ORPHAN DISEASE REGISTER
    Sanchez, Garcia J. J.
    Hill, C. A.
    Hill, D.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A453 - A453
  • [4] THE QUANTITY AND QUALITY OF EVIDENCE SUPPORTING EUROPEAN MARKETING AUTHORISATION OF ORPHAN DRUGS: COMPARISON OF RARE ONCOLOGY VERSUS RARE DISEASE
    Kelly, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S468 - S468
  • [5] Ten Years of Regulation for Orphan Medicinal Products in the EU: Characteristics Associated with Marketing Authorisation
    Putzeist, Michelle
    Heemstra, Harald E.
    Mantel-Teeuwisse, Aukje M.
    Gispen, Christine C.
    Hoes, Arno W.
    Garcia, Jordi Llinares
    Leufkens, Hubert G.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S221 - S222
  • [6] Post-authorisation assessment of orphan drugs
    Hollak, Carla E. M.
    Biegstraaten, Marieke
    Levi, Marcel
    Hagendijk, Rob
    [J]. LANCET, 2015, 386 (10007): : 1940 - 1941
  • [7] Ten years after European Regulation of Orphan Drugs
    Ayme, Segolene
    [J]. PRESSE MEDICALE, 2010, 39 (05): : 5 - 7
  • [8] European Marketing Authorisation: a long process
    Buljovcic, Z.
    [J]. BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2011, 54 (07) : 831 - 838
  • [9] ACCESS TO ORPHAN DRUGS - REGULATION WITHIN THE EUROPEAN LAW
    Aulois-Griot, M.
    Silva, M. L.
    [J]. VALUE IN HEALTH, 2018, 21 : S459 - S459
  • [10] Marketing authorisation of orphan medicines in Europe from 2000 to 2013
    Hofer, Matthias P.
    Hedman, Hanna
    Mavris, Maria
    Koenig, Franz
    Vetter, Thorsten
    Posch, Martin
    Vamvakas, Spiros
    Regnstrom, Jan
    Aarum, Stiina
    [J]. DRUG DISCOVERY TODAY, 2018, 23 (02) : 424 - 433
12345